Uncategorized
Alimera allowed to reduce size of Iluvien study in UK
The United Kingdom’s Medicines and Healthcare Products Regulatory Agency has given final approval to reduce the size of Alimera Sciences’ post-marketing study of Iluvien, according to a company press release.The study, originally intended to follow 800 patients over 5 years, has shown consistent positive safety data, leading the company to seek a smaller sample size, the release said. There are currently 550 patients enrolled.